AD/PD 2026 Archives - PharmaDeviceNews

What Spear Bio’s new pTau 217 assay reveals about where Alzheimer’s biomarker detection is heading

by Pallavi Madhiraju
March 24, 2026
0 Comments

Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer's and Parkinson's research. Read the analysis.

Pharma & Biotech

Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests

by Pallavi Madhiraju
March 23, 2026
0 Comments

Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.

Representative image of a laboratory Alzheimer’s biomarker study, highlighting plasma tau testing and cognitive decline analysis, as C2N Diagnostics advances its PrecivityTauDx programme with Phase 3 evidence for tangle biomarkers.

Medical Devices & Diagnostics

C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence

by Pallavi Madhiraju
March 22, 2026
0 Comments

C2N's eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer's patient selection. Read the analysis.